RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)
Jul 31, 2020
Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.
Read Article
The RheumNow Podcast is up - Top 13 Rheumatology Centers in the US; anakinra & colchicine in COVID, unload the loading dose, CB2 in Scleroderma.
Dr. John Cush RheumNow ( View Tweet)
Aug 02, 2020
Spanish registry of 3679 SLE pts finds 13.6% had polyautoimmunity (SLE plus another autoimmune Dz), Dx as thyroiditis (8%), Sjogrens (14%) secondary APS (14%).
Links:
Dr. John Cush RheumNow ( View Tweet)
Jul 31, 2020
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp
Dr. John Cush RheumNow ( View Tweet)
Jul 17, 2020
RheumNow Podcast – LTF – Listen to Fauci (7.17.20)
Jul 17, 2020
Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.
Ghent Univ experience and literature review shows that diffuse and localized scleroderma occurs in 2.4 to 7.4% often with Raynauds (6/8), scleroderma pattern on nailfold videocapillaroscopy and SSc-specific autoantibodies https://t.co/zDgXsuKD3p
Links:
Dr. John Cush RheumNow ( View Tweet)
Jul 16, 2020
Virtual EULAR 2020 Round Up
Jun 12, 2020
In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic
Read Article
Day 3 - Top 5 from EULAR 2020
Jun 10, 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
Day 2 – Top 5 from EULAR 2020
Jun 09, 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020.
Read Article
Yet another NEGATIVE Trial in Hand OA. Add Hand OA to the list that Includes Scleroderma, Sjogrens and CRPS as untreatable diseases with large unmet needs! https://t.co/cMMqmeo19N
Dr. John Cush RheumNow ( View Tweet)
Jun 05, 2020
First Look at COVID-19 Global Rheumatology Alliance Registry
Jun 01, 2020
Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect
Read Article
Systemic Sclerosis Future Therapies and Outcome Measures
May 19, 2020
Nagaraja, Khanna and colleagues have published an overview of current and future therapies in patients with systemic sclerosis (SSc) and have reviewed the potential outcome measures for this difficult autoimmune disorder. Notably there have been several novel agents studied in recent years,
Read Article
RheumNow Podcast – The Beat Goes On (5.8.20)
May 07, 2020
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Lenabasum Encouraging in Systemic Sclerosis
Apr 30, 2020
The oral cannabinoid receptor type 2 (CB2) agonist lenabasum showed promising results for systemic sclerosis (SSc) in a phase II study.
At week 16, the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) increased to 0.33 among
Read Article
RheumNow Podcast – In Times of Trouble (4.24.20)
Apr 24, 2020
Dr Jack Cush reviews the news, journal reports, twitter feed and COVID developments from the past week on RheumNow.com
Read Article
Treatment of Statin-induced anti-HMGCR myopathy
Jan 10, 2020
Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of
Read Article
CRP in SSc: Identifying a Severe Phenotype
Dec 12, 2019
Patients with systemic sclerosis (SSc) who have persistent inflammation -- characterized by consistently elevated levels of C-reactive protein (CRP) -- have more severe disease and worse outcomes, a retrospective study confirmed.
In a cohort of 131 patients, those with the inflammatory
Read Article
RheumNow Podcast – Believe in Vitamin D or Rituximab? (9.20.19)
Sep 20, 2019
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
RheumNow Podcast – The End of Arthritis (9.13.19)
Sep 13, 2019
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers
Sep 10, 2019
Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.
Read Article
Nintedanib FDA Approved for Scleroderma Lung Disease
Sep 09, 2019
Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD.
ILD as a complication of SSc may lead to progressive loss of
RheumNow Podcast – More Than a Spot of Tea (8.2.19)
Aug 02, 2019
Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com:
MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.
Abatacept Disappoints in Systemic Sclerosis
Jul 29, 2019
A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)
A total of 169 dsSSc
Read Article
RheumNow Podcast – FDA Hyperactivity (7.26.19)
Jul 26, 2019
Dr. Jack Cush reviews the news, journal reports, and FDA releases and deliberations covered this past week on RheumNow.com
Read Article
FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease
Jul 25, 2019
The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.
Read ArticleRecent Blogs
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Post
